China's Jiangsu Says it Will Support Pharmaceutical Firms' Global M&A, Licensing

JPMorgan Chase & Co.'S Short Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Increases to 3.72% on August 21 from 2.57% - HKEX

Singapore's GIC Boosts Stake in Hengrui Pharma With HK$185 Million Share Purchase

HENGRUI PHARMA's HRG2010 Capsule Marketing Application Accepted by NMPA

Hengrui Pharma's Half-Year Report: Heavy Spending Fails to Drive Growth as Former Sector Leader Struggles with Revenue Without Profit Expansion

Hengrui Pharma's Growth Architecture Shifts: Second Growth Engine Accelerates as Global Valuation Framework Expands

Jiangsu Hengrui Pharmaceuticals- Nmpa Notice Approving Developed Class 1 Innovative Drug Licancopan Fumarate (Hrs-5965) Capsules for Marketing

HENGRUI PHARMA (01276) Gets Clinical Trial Approval for SHR-7012 Injection Targeting Cutaneous Lupus Erythematosus

Jiangsu Hengrui Pharmaceuticals Says Chinese Regulator Approved Hrs-5965 Capsule for Market

Jiangsu Hengrui Hong Kong Shares Hit Record Low on Quarterly Profit Miss

Hengrui Pharma Appoints Tian Fei as New Board Secretary

Hengrui Pharma Launches RMB 1 Billion-RMB 2 Billion A-Share Buyback, Caps Price at RMB 81.78

HENGRUI PHARMA Proposes New H-Share Incentive Scheme for 2026

Hengrui Pharma FY26 H1 Profit Attributable to Owners Rises 0.3% to RMB 4.47 Billion; Revenue Falls 1.9% to RMB 15.46 Billion

Hengrui Pharma's First-Half Results Unveil Strategic Shifts: From Innovative Drugs to NewCo Expansion

Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum

Jiangsu Hengrui Pharmaceuticals Says it Plans to Buy Back Co A-Shares Worth 1-2 Bln Yuan

China's Top Drugmaker Hengrui Reports Slight Rise in H1 Profit

Jiangsu Hengrui Pharmaceuticals H1 Net Profit up 0.34% Y/Y

Hengrui Pharma Gets China Nod For Inflammatory Bowel Injection Clinical Trial